PMID-19035858 – Degarelix Phase III vs Leuprolide in Prostate Cancer

PMID-19035858 – Degarelix Phase III vs Leuprolide in Prostate Cancer

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schroder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-8.

Quick Reference

Property Value
PMID 19035858
DOI 10.1111/j.1464-410X.2008.08183.x
Year 2008
Journal BJU International
Study Type RCT (Phase III)
Evidence Level I
Sample 610 patients with prostate cancer
Peptide(s) Studied Degarelix, Leuprolide

Key Findings

  • Degarelix achieved castrate testosterone levels (<0.5 ng/mL) in 96% of patients within 3 days vs 0% with leuprolide at the same timepoint
  • No testosterone flare observed with degarelix (a key advantage over GnRH agonists)
  • PSA levels at days 14 and 28 were significantly lower with degarelix (P<0.001)
  • Long-term testosterone suppression at 12 months was comparable: 97-98% degarelix vs 96% leuprolide
  • Injection-site reactions were more common with degarelix (40%) vs leuprolide (<1%)
  • Urinary tract infections were more common with leuprolide (9% vs 3%)
  • Degarelix eliminated the need for anti-androgen flare protection

Study Design

Phase III, randomized, open-label, parallel-group, multicenter study comparing two degarelix dosing regimens (240/80 mg and 240/160 mg) versus leuprolide 7.5 mg monthly in 610 patients with prostate cancer requiring androgen deprivation therapy. Primary endpoint was testosterone suppression to castrate levels over 12 months.

Limitations

  • Open-label design
  • Injection-site reactions higher with SubQ degarelix vs IM leuprolide (different routes confound comparison)
  • Not powered for survival or disease progression endpoints
  • No comparison with other GnRH antagonists

Clinical Relevance

This pivotal Phase III trial established degarelix as the first GnRH antagonist approved for prostate cancer, demonstrating its key clinical advantage: immediate testosterone suppression without the flare phenomenon that occurs with GnRH agonists. This is particularly important for patients with impending spinal cord compression or urinary obstruction, where testosterone flare could worsen symptoms. The study led to FDA approval of degarelix (Firmagon) in 2008.

Related

#research #RCT #peptide #sexual-health #evidence-level-I